Description

SHL Telemedicine Ltd., operating with its subsidiaries, specializes in the development and distribution of individualized telehealth services and medical devices. Their reach extends across Israel, Europe, and various international territories. The company's offerings include a suite of personal 12-lead ECG devices: the Smartheart, a mobile unit designed for the early detection of heart attacks; the CardioSen'C, a personal cellular-digital transmitter; the portable Cardio'B; and the handheld Cardio Beeper 12/12, which is capable of transmitting a complete ECG reading to a centralized monitoring facility. Beyond cardiac diagnostics, SHL Telemedicine provides a variety of other remote health monitoring technologies. These encompass a central communication module, a telecommunication device that relays medical data from diverse monitoring instruments to their telemedicine centers; TeleWeight, a trans-telephonic system for personal weight management; TelePress, a remote blood pressure monitoring device for home use; TeleBreather, an electronic handheld instrument for assessing lung function; and the TelePulse Oximeter, an electronic handheld diagnostic tool for measuring blood oxygen saturation levels and pulse rate. These telemedicine solutions and devices are delivered to subscribers utilizing both telephonic and internet communication channels. The company caters to a wide array of clients, including individual patients, health insurance providers, hospitals, clinics, physicians, and other healthcare organizations. SHL Telemedicine is actively involved in strategic alliances. One such partnership with the Mayo Clinic focuses on evaluating the frequency of emergency department visits, re-hospitalizations, and significant adverse cardiovascular events over a 90-day period following a patient's initial heart attack hospitalization, specifically for those using the FDA-approved SmartHeart 12-lead ECG. Furthermore, a collaboration with the Hebrew University of Jerusalem and the Hadassah Medical Center is dedicated to creating an artificial intelligence tool aimed at predicting future life-threatening cardiac events based on 12-lead ECG monitoring. Established in 1987, SHL Telemedicine Ltd. is headquartered in Tel Aviv, Israel.